RBC Bioscience Corporation (TPEX:6848)

Market Cap	279.76M +12.9%
Revenue (ttm)	219.71M +7.0%
Net Income	23.54M +9.2%
EPS	1.64 +9.3%
Shares Out	14.27M
PE Ratio	11.95
Forward PE	n/a
Dividend	1.50 (7.75%)
Ex-Dividend Date	Jul 9, 2026

Volume	2,010
Open	19.70
Previous Close	19.35
Day's Range	19.60 - 19.70
52-Week Range	14.30 - 25.05
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About RBC Bioscience

RBC Bioscience Corporation manufactures and sells reagents and devices for life science and molecular diagnosis. It offers robotic bench-top workstation for nucleic acid purification under the MagCore Plus II and Giga Automated Nucleic Acid Extractor names; MagCore Super Automated Nucleic Acid Extractor, an automated workstation for nucleic acid extraction; and MagCore EDA Automatic Extraction and Smart PCR Setup, an instrument for nucleic acid extraction and PCR setup pre-treatment. The company also provides NGS, genomic DNA, viral nucleic aci...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 50
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6848

Financial Performance

In 2025, RBC Bioscience's revenue was 219.71 million, an increase of 7.05% compared to the previous year's 205.25 million. Earnings were 23.54 million, an increase of 9.17%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 22, 2026

Data Sources Report a data error